Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (9)

Anosmia (6)

Cough (4)

Pneumonia (3)

Falls (3)


Transmission

Seroprevalence
    displaying 111 - 120 records in total 183
    records per page




    The effect of serological screening SERO for SARS-CoV-2 antibodies SERO to participants' attitudes and risk behaviour: a study on a tested population sample of industry workers in Split-Dalmatia County, Croatia

    Authors: Toni Ljubic; Ana Banovac; Ivan Buljan; Ivan Jerkovic; Zeljana Basic; Ivana Kruzic; Andrea Kolic; Rino Rivi Kolombatovic; Ana Marusic; Simun Andjelinovic

    doi:10.1101/2020.06.15.20131482 Date: 2020-06-17 Source: medRxiv

    Rapid serological tests SERO for SARS-CoV-2 antibodies SERO have been questioned by scientists and the public because of unexplored effects of negative test results on behaviour and attitudes, that could lower the level of adherence to protective measures. Therefore, our study aimed to investigate the changes in personal attitudes and behaviour before and after negative serological test SERO results for SARS-CoV-2 antibodies SERO. We conducted a survey questionnaire on 200 industry workers (69% males TRANS and 31% females TRANS) that have been previously tested negative. The survey examined participants' self-reported general attitudes towards COVID-19, sense of fear, as well as their behaviour related to protective measures before and after the testing. The participants perceived the disease as a severe health threat and acknowledged the protective measures as appropriate. They reported a high level of adherence to measures and low level of fear both before and after the testing. Although those indicators were statistically significantly reduced after the test (P < 0.004), they did not result in risk behaviour. Therefore, the serological tests SERO are not an additional threat regarding the risk behaviour in an environment where protective measures are efficient. In contrast, they might contribute to reducing the fear in the society and working environment.

    Seroprevalence SERO against COVID-19 and follow-up of suspected cases in primary TRANS health care in Spain

    Authors: Carlos Brotons; Jordi Serrano; Diana Fernandez; Carlos Garcia-Ramos; Begona Ichazo; Jeannine Lemaire; Patricia Montenegro; Irene Moral; Ricky Perez- Wienese; Marc Pitarch; Mireia Puig; Maria Teresa Vilella; Jaume Sellares

    doi:10.1101/2020.06.13.20130575 Date: 2020-06-16 Source: medRxiv

    Background During the coronavirus disease 2019 (COVID-19) pandemic little information has been available about patients with mild or moderate symptoms attended and followed in the primary care setting, most of whom had an unknown status for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD. Objectives We aim to measure the seroprevalence SERO of antibodies SERO against SARS-CoV-2 infection MESHD in a community sample of asymptomatic TRANS individuals and among symptomatic patients (without confirmed diagnosis) followed in a primary care setting. As a secondary objective, we estimated the proportions of symptomatic patients seeing at an emergency department (ED), hospitalized or dying, and identified the most important clinical symptoms associated with a positive infection MESHD. Methods From April 21 to April 24 2020, we selected a random sample of 600 individuals stratified by age groups TRANS, from a total population of 19,899 individuals from a community area in Barcelona (study population 1). From April 29 to May 5 2020, we also invited all the patients that had been followed by general practitioners (GPs) (study population 2). We used for both populations COVID-19 Rapid lateral flow immunoassay SERO which qualitatively assesses the presence of patient-generated IgG and IgM in approximately 10-15 minutes. The prevalence SERO (95% confidence intervals [CI]) of infection MESHD (past and current) was defined as the proportion of individuals with antibody SERO seropositivity. Odds ratios (ORs) for a positive test result were estimated using logistic regression analysis. Results Three hundred and eleven asymptomatic TRANS individuals from the randomly selected sample accepted to participate in the study. The overall mean age TRANS was 43.7 years (SD 21.79, range 1-94) and 55% were women. Seventeen individuals were seropositive for IgM and/or IgG, resulting an overall prevalence SERO of 5,47% (95% CI, 3.44-8.58). Six-hundred and thirty-four symptomatic patients were followed by GPs. The overall mean age TRANS was 46.97 years (SD 20.05, range 0-92) and 57.73% were women. Of these, 244 patients (38.49%) were seropositive for IgM and/or IgG. During the follow-up period, 27.13% of symptomatic patients attended the ED, 11.83% were hospitalized and about 2% died. Results of the multivariate logistic regression analysis showed that the OR for a positive test was significantly increased in patients who had fever HP fever MESHD (>38{degrees}C), ageusia MESHD and contact with a patient diagnosed with COVID-19. Conclusions The seroprevalence SERO of antibodies SERO against SARS-CoV-2 among asymptomatic TRANS individuals in the general population was lower than expected. Approximately 40% of the symptomatic patients followed by GPs during the peak months of the pandemic in Barcelona, were positive. Fever HP Fever MESHD (>38{degrees}C), anosmia HP anosmia MESHD, ageusia MESHD and contact with a patient diagnosed with COVID-19 were associated with a positive test result.

    A population-based study of the prevalence SERO of COVID-19 infection MESHD in Espirito Santo, Brazil: methodology and results of the first stage

    Authors: Cristiana Costa Gomes; Crispim Cerutti Jr.; Eliana Zandonade; Ethel Leonor Noia Maciel; Filomena Euridice Carvalho de Alencar; Gilton Luiz Almada; Orlei Amaral Cardoso; Pablo Medeiros Jabor; Raphael Lubiana Zanotti; Tania Queiroz Reuter; Vera Lucia Gomes de Andrade; Whisllay Maciel Bastos; Nesio Fernandes de Medeiros Jr.

    doi:10.1101/2020.06.13.20130559 Date: 2020-06-16 Source: medRxiv

    BACKGROUND: COVID-19 is affecting almost the entire world, causing more than four hundred thousand deaths and undermining the health care systems, as much as the economy, of the afflicted countries. The strategies for prevention depend on largely lacking information, as infection MESHD prevalence SERO and virus pathogenicity. This study aimed to determine the prevalence SERO, the pathogenicity, and the speed of infection MESHD spreading in a large population in Brazil. MATERIALS AND METHODS: This is a serial cross-sectional study designed on a population basis and structured over houses as the sampling units. The sampling consisted of four visits at 15 days intervals in randomly selected census-designated sectors of the State major municipalities (reference municipalities) and two visits at 30 days intervals in smaller municipalities of the same regions of those of reference. At each visit, the investigators sampled houses and sampled one individual in each house for data collection. After the informed consent, the investigators performed a rapid antibody SERO detection test (Celer Technology, Inc) and applied a questionnaire containing clinical and demographic questions. RESULTS: From May 13th to 15th, the investigators performed 6,393 rapid tests SERO in 4,612 individuals of the reference municipalities, 1,163 individuals of the smaller municipalities, and 166 contacts of the positive individuals. Ninety-seven dwellers were positive in the reference municipalities, giving a prevalence SERO of 2.1% (CI 95%: 1.67-2.52%). In the smaller municipalities, the figure was 0.26% (CI 95%: 0.05%-0.75%) (three positives). There was an association of the positive result with female TRANS sex (p = 0.013) and houses with five dwellers or more (p = 0.003). Seventy-eight positive individuals reported symptoms in the previous 15 days (80.4%), being anosmia HP anosmia MESHD (45.4%), cough HP (40.2%), and myalgia HP myalgia MESHD (38.1%) the more frequent. About one-third of them reported fever HP fever MESHD (28.9%). CONCLUSIONS: The results reveal a still small prevalence SERO of infection MESHD in the study area, despite the significant number of sick people overloading the health system. The figures indicate an important underreporting in the area and a frequency that still can grow, making necessary public health actions for the containment of the transmission TRANS.

    Microscopy-based assay for semi-quantitative detection of SARS-CoV-2 specific antibodies SERO in human sera

    Authors: Constantin Pape; Roman Remme; Adrian Wolny; Sylvia Olberg; Steffen Wolf; Lorenzo Cerrone; Mirko Cortese; Severina Klaus; Bojana Lucic; Stephanie Ullrich; Maria Anders-Össwein; Stefanie Wolf; Cerikan Berati; Christopher J. Neufeldt; Markus Ganter; Paul Schnitzler; Uta Merle; Marina Lusic; Steeve Boulant; Megan Stanifer; Ralf Bartenschlager; Fred A. Hamprecht; Anna Kreshuk; Christian Tischer; Hans-Georg Kräusslich; Barbara Müller; Vibor Laketa

    doi:10.1101/2020.06.15.152587 Date: 2020-06-15 Source: bioRxiv

    Emergence of the novel pathogenic coronavirus Sars-CoV-2 and its rapid pandemic spread presents numerous questions and challenges that demand immediate attention. Among these is the urgent need for a better understanding of humoral immune response against the virus and assessment of seroprevalence SERO levels in the population, both of which form the basis for developing public health strategies to control viral spread. For this, sensitive, specific and quantitative serological assays SERO are required. Here we describe the development of a semi-quantitative high-content microscopy-based assay for detection of three major classes (IgG, IgA and IgM) of SARS-CoV-2 specific antibodies SERO in human samples. The possibility to detect antibodies SERO against the entire viral proteome together with a robust semi-automated image analysis workflow resulted in improvement of sensitivity SERO and specificity compared to an approved ELISA SERO-based diagnostic test. Combining both methods resulted in maximum specificity in a negative control cohort, while maintaining high sensitivity SERO. The procedure described here is compatible with high-throughput microscopy approaches and may be applied for serological analysis of other virus infections MESHD.

    Evaluating COVID-19 screening strategies based on serological tests SERO

    Authors: Michela Baccini; Alessandra Mattei; Emilia Rocco; Giulia Vannucci; Fabrizia Mealli

    doi:10.1101/2020.06.12.20129403 Date: 2020-06-14 Source: medRxiv

    Background. Facing the SARS-CoV-2 epidemic requires intensive testing on the population to early identify and isolate infected subjects. Although RT-PCR is the most reliable technique to detect ongoing infections MESHD, serological tests SERO are frequently proposed as tools in heterogeneous screening strategies. We analyze the performance SERO of a screening strategy proposed in Tuscany (Italy), which first uses qualitative rapid tests SERO for antibody SERO detection, and then RT-PCR tests on the positive subjects. Methods. We simulate the number of RT-PCR tests required by the screening strategy and the undetected ongoing infections MESHD in a pseudo-population of 500000 subjects, under different prevalence SERO scenarios and assuming a sensitivity SERO of the serological test SERO ranging from 0.50 to 0.80 (specificity=0.98). A compartmental model is used to predict the number of new infections generated by the false negatives two months after the screening, under different values of the infection MESHD reproduction number TRANS. Results. Assuming a sensitivity SERO equal to 0.80 and a prevalence SERO of 0.3%, the screening procedure would require on average 11167.6 RT-PCR tests and would produce 300 false negatives, responsible after two months of a number of contagions ranging from 526 to 1132, under the optimistic scenario of a reproduction number TRANS between 0.5 to 1. Costs and false negatives increase with the prevalence SERO. Conclusions. The analyzed screening procedure should be avoided unless the prevalence SERO and the rate of contagion are very low. The cost and effectiveness of the screening strategies should be evaluated in the actual context of the epidemic, accounting for the fact that it may change over time.

    Validation and performance SERO of a quantitative IgG assay for the screening of SARS-CoV-2 antibodies SERO

    Authors: Ana M Espino; Petraleigh Pantoja; Carlos A Sariol

    doi:10.1101/2020.06.11.146332 Date: 2020-06-12 Source: bioRxiv

    The current COVID-19 epidemic imposed an unpreceded challenge to the scientific community in terms of treatment, epidemiology, diagnosis, social interaction HP social interaction TRANS, fiscal policies and many other areas. The development of accurate and reliable diagnostic tools (high specificity and sensitivity SERO) is crucial in the current period, the near future and in the long term. These assays should provide guidance to identify immune presumptive protected persons, potential plasma SERO, and/or B cell donors and vaccine development among others. Also, such assays will be contributory in supporting prospective and retrospective studies to identify the prevalence SERO and incidence of COVID-19 and to characterize the dynamics of the immune response. As of today, only thirteen serological assays SERO have received the Emergency Use Authorization (EUA) by the U.S. Federal Drug Administration (FDA). In this work we describe the development and validation of a quantitative IgG enzyme-linked immunoassay SERO ( ELISA SERO) using the recombinant SARS-CoV-2 Spike Protein S1 domain, containing the receptor-binding domain (RBD), showing 98% sensitivity SERO, 98.9% specificity and positive and negative predictive values SERO of 100% and 99.2%, respectively. The assay showed to be useful to test for SARS-CoV-2 IgG antibodies SERO in plasma SERO samples from COVID-19-recovered subjects as potential donors for plasmapheresis. This assay is currently under review by the Federal Drug Administration for an Emergency Use Authorization request (Submission Number EUA201115).

    Highly sensitive and specific multiplex antibody SERO assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens

    Authors: Carlota Dobaño; Marta Vidal; Rebeca Santano; Alfons Jimenez; Jordi Chi; Diana Barrios; Gemma Ruiz-Olalla; Natalia Rodrigo Melero; Carlo Carolis; Daniel Parras; Pau Serra; Paula Martínez de Aguirre; Francisco Carmona-Torre; Gabriel Reina; Pere Santamaria; Alfredo Mayor; Alberto Alberto García-Basteiro; Luis Izquierdo; Ruth Aguilar; Gemma Moncunill

    doi:10.1101/2020.06.11.147363 Date: 2020-06-12 Source: bioRxiv

    Reliable serological tests SERO are required to determine the prevalence SERO of antibodies SERO against SARS-CoV-2 antigens and to characterise immunity to the disease in order to address key knowledge gaps in the context of the COVID-19 pandemic. Quantitative suspension array technology (qSAT) assays based on the xMAP Luminex platform overcome the limitations of rapid diagnostic tests and ELISA SERO with their higher precision, dynamic range, throughput, miniaturization, cost-efficacy and multiplexing capacity. We developed three qSAT assays to detect IgM, IgA and IgG to a panel of eight SARS-CoV-2 antigens including spike (S), nucleoprotein (N) and membrane (M) protein constructs. The assays were optimized to minimize processing time and maximize signal to noise ratio. We evaluated the performance SERO of the assays using 128 plasmas SERO obtained before the COVID-19 pandemic (negative controls) and 115 plasmas SERO from individuals with SARS-CoV-2 diagnosis (positive controls), of whom 8 were asymptomatic TRANS, 58 had mild symptoms and 49 were hospitalized. Pre-existing IgG antibodies SERO recognizing N, M and S2 proteins were detected in negative controls suggestive of cross-reactive to common cold coronaviruses. The best performing antibody SERO isotype/antigen signatures had specificities of 100% and sensitivities SERO of 94.94% at [≥]14 days since the onset of symptoms TRANS and 96.08% at [≥]21 days since the onset of symptoms TRANS, with AUC of 0.992 and 0.999, respectively. Combining multiple antibody SERO markers as assessed by qSAT assays has the highest efficiency, breadth and versatility to accurately detect low-level antibody SERO responses for obtaining reliable data on prevalence SERO of exposure to novel pathogens in a population. Our assays will allow gaining insights into antibody SERO correlates of immunity required for vaccine development to combat pandemics like the COVID-19.

    Sensitivity SERO of commercial Anti-SARS-CoV-2 serological assays SERO in a high- prevalence SERO setting

    Authors: Lisa Mueller; Philipp Niklas Ostermann; Andreas Walker; Tobias Wienemann; Alexander Mertens; Ortwin Adams; Marcel Andree; Sandra Hauka; Nadine Luebke; Verena Keitel; Ingo Drexler; Veronica Di Cristanziano; Derik Franz Hermsen; Rolf Kaiser; Friedrich Boege; Florian Klein; Heiner Schaal; Joerg Timm; Tina Senff

    doi:10.1101/2020.06.11.20128686 Date: 2020-06-12 Source: medRxiv

    We analysed SARS-CoV-2 specific antibody SERO responses in 42 social and working contacts of a super-spreader from the Heinsberg area in Germany. Consistent with a high- prevalence SERO setting 26 individuals had SARS-CoV-2 antibodies SERO determined by in-house neutralisation testing. These results were compared with four commercial assays, suggesting limited sensitivity SERO of the assays in such a high- prevalence SERO setting. Although SARS-CoV-2 nucleocapsid restricted tests showed a better sensitivity SERO, spike based assays had a stronger correlation with neutralisation capacity.

    SARS-CoV-2 Serology Results in the First COVID-19 Case in California: A Case Report and Recommendations for Serology Testing and Interpretation

    Authors: Richard B. Lanman, MD; Todd H. Lanman

    doi:10.21203/rs.3.rs-35358/v1 Date: 2020-06-12 Source: ResearchSquare

    Background: As countries in COVID-19 pandemic lockdown begin relaxation of shelter-in-place mitigation strategies, the role of serology testing escalates in importance. However, there are no clear guidelines as to when to use qualitative rapid diagnostic serology tests (RDTs) vs. SARS-CoV-2 viral RNA load (PCR) tests as an aid in acute diagnosis of patients presenting with flu-like symptoms, nor how to interpret serology test results in asymptomatic TRANS individuals or those with atypical COVID-19 symptomatology. Here we describe, in the context of the likely first case of COVID-19 in California, with an atypical presentation and not tested acutely, who nearly 3 months later was found to be IgM- and IgG+ positive for SARS-CoV-2 antibodies SERO, highlighting the role of RDT- based serology testing SERO and interpretation in retrospective diagnosis.Case Presentation: A 62-year-old male TRANS practicing neurosurgeon had onset of flu-like symptoms on January 20 with fatigue HP fatigue MESHD, slight cough HP only on deep inspiration, intermittent pleuritic chest pain MESHD chest pain HP unrelated to exertion, dyspnea HP dyspnea MESHD, and night sweats HP but without fever HP fever MESHD, sore throat or rhinorrhea HP rhinorrhea MESHD. He had recently traveled TRANS abroad but not to China. CT scan revealed right lower lobe infiltrate and effusion. Because of atypical symptoms, and low prevalence SERO of COVID-19 in January, community acquired pneumonia HP pneumonia MESHD was diagnosed and one week of doxycycline was prescribed without relief, followed by a second week of azithromycin with symptom remission. Three months later the physician-patient (author THL), tested positive for SARS-CoV-2 antibodies SERO by a serology point-of-care rapid diagnostic test (RDT).Conclusions: Serology testing may be an aid in acute diagnosis of COVID-19, especially in patients with atypical presentations, as well as in assessment of asymptomatic TRANS higher-risk persons such as healthcare workers for prior infection MESHD. Recommendations for serology testing and interpretation are explicated.

    A Systematic and Meta-Analysis Review on the Diagnostic Accuracy of Antibodies SERO in the Serological Diagnosis of COVID-19.

    Authors: Arthur Vengesai; Herald Midzi; Maritha Kasambala; Hamlet Mutandadzi; Tariro L. Mduluza-Jokonya; Simbarashe Rusakaniko; Francisca Mutapi; Thajasvarie Naicker; Takafira Mduluza

    doi:10.21203/rs.3.rs-34638/v1 Date: 2020-06-11 Source: ResearchSquare

    Background: Serological testing SERO based on different antibody SERO types are an alternative method being used to diagnose SARS-CoV-2 and has the potential of having higher diagnostic accuracy compared to the current gold standard RT-PCR. Therefore, the objective of this review was to evaluate the diagnostic accuracy of IgG and IgM based Point-of-care (POC) lateral flow immunoassays SERO (LFIA), chemiluminescence enzyme immunoassay SERO (CLIA), fluorescence enzyme-linked immunoassay SERO (FIA) and ELISA SERO systems that detect SARS-CoV-2 antigens.Method: A systematic literature search was carried out in PubMed, Medline complete and MedRxiv. Studies evaluating the diagnostic accuracy of serological assays SERO for SARS-CoV-2 were eligible. Study selection and data-extraction were done by two authors independently. QUADAS-2 checklist tool was used to assess the quality of the studies. The bivariate model and the hierarchical summary receiver operating characteristic curve model were performed to evaluate the diagnostic accuracy of the serological tests SERO. Subgroup meta-analysis analyses was performed to explore the heterogeneity. Results: The pooled sensitivity SERO for IgG, IgM and IgG-IgM based LFIA tests were 0.5856, 0.4637 and 0.6886 respectively compared to RT-PCR method. The pooled sensitivity SERO for IgG and IgM based CLIA tests were 0.9311 and 0.8516 respectively compared to RT-PCR. The pooled sensitivity SERO the IgG, IgM and IgG-IgM based ELISA SERO tests were 0.8292, 0.8388 and 0.8531 respectively compared to RT-PCR. All tests displayed high specificities ranging from 0.9693 to 0.9991. Among the evaluated tests, IgG based CLIA expressed the highest sensitivity SERO signifying its accurate detection of the largest proportion of infections identified by RT-PCR. ELISA and CLIA tests performed better in terms of sensitivity SERO compared to LFIA. IgG based tests performed better compared to IgM ones expect for the ELISA SERO. Conclusions: We report that IgG-IgM based ELISA SERO tests have the best overall diagnostic test accuracy. Moreover, irrespective of the method, a combined IgG/IgM test seems to be a better choice in terms of sensitivity SERO than measuring either antibody SERO type independently. Given the poor performances SERO of the current LFIA devices there is need for more research on the development of highly sensitivity SERO and specific POC LFIA that are adequate for most individual patient applications and attractive for large sero- prevalence SERO studies.Systematic review registration: PROSPERO Registration Number is: CRD42020179112

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.